Connect with us


Coronavirus | Novavax reports 96.4% efficacy on original virus

NovaVax, the US-based biotechnology company Covid-19 in the development of a recombinant vaccine, has announced the final efficiency of 96.4% for a mild, moderate and severe disease caused by the first phase of the SARS-Cov-2 strain.

View Full Article


This news content is a computer generated summarized version of the original article and the authenticity of the original content has not been verified. Please click on the View Article button to refer to the actual content.